In order to be relevant and appropriate for decision making health economic evaluations need to:
• Assess costs and health outcomes during the time horizon they are expected to differ between investigated strategies – which often implied a life time perspective
• Incorporate all relevant evidence
• Assess cost-effectiveness in sub groups
• Handle uncertainty appropriately
• Assess the value of further research
To achieve this, decision-analytic modelling is required. Randomized clinical trials is another important tool, although it is important to remember that they primarily contribute with unbiased estimated of treatment effect. Models and clinical trials are thus complements rather than substitutes. Within this field we are working with applied and methodological research.
Ongoing projects
• Economic evaluation of screening for abdominal aortic aneurysm• Economic evaluation of an emerging non-invasive diagnostic procedure to determine liver function (the 4LIFE study)
• Decision-analytic modelling of cardiovascular disease with a specific focus on long-term disease progression and repeated events
Finalized projects
• Economic evaluation of ticagrelor in patients with acute coronary syndrome (based on the large multinational PLATO study)• Economic evaluation of an invasive management strategy in patients with non-ST-elevation acute coronary syndrome (based on the RITA-3 study)
• Systematic review and economic evaluation of pharmaceutical treatments in patients with depression
• Systematic review and economic evaluation of circulating biomarkers to prioritize patients on the waiting list for coronary artery bypass grafting
